Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (Q34614776)

3 August 2017

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study (English)

1 reference

multicenter clinical trial

3 August 2017

0 references

0 references

11

Jean-Jacques Grob

0 references

Dirk Schadendorf

8

object named as

Dirk Schadendorf

1 reference

3 August 2017

1

Jedd D Wolchok

1 reference

3 August 2017

Bart Neyns

2

1 reference

3 August 2017

Gerald Linette

3

1 reference

3 August 2017

Sylvie Negrier

4

1 reference

3 August 2017

Jose Lutzky

5

1 reference

3 August 2017

Luc Thomas

6

1 reference

3 August 2017

William Waterfield

7

1 reference

3 August 2017

Michael Smylie

9

1 reference

3 August 2017

Troy Guthrie

10

1 reference

3 August 2017

Jean-Jacques Grob

11

1 reference

3 August 2017

Jason Chesney

12

1 reference

3 August 2017

Kevin Chin

13

1 reference

3 August 2017

Kun Chen

14

1 reference

3 August 2017

Axel Hoos

15

1 reference

3 August 2017

Steven J O'Day

16

1 reference

3 August 2017

Celeste Lebbé

17

1 reference

3 August 2017

language of work or name

1 reference

8 December 2009

1 reference

Lancet Oncology Commission

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

155-164

1 reference

3 August 2017

2

1 reference

Management of cutaneous melanoma

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Cutaneous melanoma: available therapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Update on anti-CTLA-4 antibodies in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Ipilimumab: controversies in its development, utility and autoimmune adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970334-1

7 January 2021

10.1016/S1470-2045(09)70334-1

Identifiers

DOI

1 reference

3 August 2017

1 reference